Terms: = Prostate cancer AND ATRX, P46100, ZNF-HX, XNP, XH2, SHS, SFM1, RAD54, MRXHF1, MGC2094, ATR2, 546 AND Treatment
41 results:
1. Costs of radium-223 and the pharmacy preparation
Quist SW; Paulissen JHJ; Wyndaele DNJ; Nagarajah J; Freriks RD
J Med Econ; 2023; 26(1):366-375. PubMed ID: 36905581
[TBL] [Abstract] [Full Text] [Related]
2. Pan-cancer association of DNA repair deficiencies with whole-genome mutational patterns.
Sørensen SG; Shrikhande A; Poulsgaard GA; Christensen MH; Bertl J; Laursen BE; Hoffmann ER; Pedersen JS
Elife; 2023 Mar; 12():. PubMed ID: 36883553
[TBL] [Abstract] [Full Text] [Related]
3. Acute toxicity and health-related quality of life outcomes of localized prostate cancer patients treated with magnetic resonance imaging-guided high-dose-rate brachytherapy: A prospective phase II trial.
Sanmamed N; Adleman J; Berlin A; Borg J; Lao B; Weersink R; Simeonov A; Rink A; Beiki-Ardakani A; Menard C; Chung P; Helou J
Brachytherapy; 2023; 22(1):58-65. PubMed ID: 36414526
[TBL] [Abstract] [Full Text] [Related]
4. Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive prostate cancer: A Network Meta-analysis.
Roy S; Sayyid R; Saad F; Sun Y; Lajkosz K; Ong M; Klaassen Z; Malone S; Spratt DE; Wallis CJD; Morgan SC
Eur Urol Oncol; 2022 Oct; 5(5):494-502. PubMed ID: 35811293
[TBL] [Abstract] [Full Text] [Related]
5. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.
Sweeney C; Bracarda S; Sternberg CN; Chi KN; Olmos D; Sandhu S; Massard C; Matsubara N; Alekseev B; Parnis F; Atduev V; Buchschacher GL; Gafanov R; Corrales L; Borre M; Stroyakovskiy D; Alves GV; Bournakis E; Puente J; Harle-Yge ML; Gallo J; Chen G; Hanover J; Wongchenko MJ; Garcia J; de Bono JS
Lancet; 2021 Jul; 398(10295):131-142. PubMed ID: 34246347
[TBL] [Abstract] [Full Text] [Related]
6. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
Fumet JD; Limagne E; Thibaudin M; Truntzer C; Bertaut A; Rederstorff E; Ghiringhelli F
BMC Cancer; 2020 Aug; 20(1):748. PubMed ID: 32778095
[TBL] [Abstract] [Full Text] [Related]
7. Scintigraphic load of bone disease evaluated by DASciS software as a survival predictor in metastatic castration-resistant prostate cancer patients candidates to 223RaCl treatment.
Frantellizzi V; Pani A; Ippoliti MD; Farcomeni A; Aloise I; Colosi M; Polito C; Pani R; Vincentis G
Radiol Oncol; 2019 Dec; 54(1):40-47. PubMed ID: 31855572
[TBL] [Abstract] [Full Text] [Related]
8. Clinical characteristics and outcomes of robot-assisted laparoscopic radical prostatectomy in HIV-positive patients: a nationwide population-based analysis.
Han H; Ye C; Tang Z; Qin Y; Ruan Y; Cao Y; He J
Int Urol Nephrol; 2020 Mar; 52(3):481-487. PubMed ID: 31679137
[TBL] [Abstract] [Full Text] [Related]
9. Management of erectile dysfunction after prostate cancer treatment: cross-sectional surveys of the perceptions and experiences of patients and healthcare professionals in the UK.
Dyer A; Kirby M; White ID; Cooper AM
BMJ Open; 2019 Oct; 9(10):e030856. PubMed ID: 31585974
[TBL] [Abstract] [Full Text] [Related]
10. Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre.
Haran C; McBean R; Parsons R; Wong D
J Med Imaging Radiat Oncol; 2019 Aug; 63(4):495-499. PubMed ID: 30972933
[TBL] [Abstract] [Full Text] [Related]
11. Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical prostatectomy after an Initial Period of Surveillance.
Balakrishnan AS; Cowan JE; Cooperberg MR; Shinohara K; Nguyen HG; Carroll PR
J Urol; 2019 Sep; 202(3):506-510. PubMed ID: 30958738
[TBL] [Abstract] [Full Text] [Related]
12. Prediction of Time to Hormonal treatment Failure in Metastatic Castration-Sensitive prostate cancer with
Jadvar H; Velez EM; Desai B; Ji L; Colletti PM; Quinn DI
J Nucl Med; 2019 Nov; 60(11):1524-1530. PubMed ID: 30926649
[TBL] [Abstract] [Full Text] [Related]
13. Individual prognosis at diagnosis in nonmetastatic prostate cancer: Development and external validation of the PREDICT prostate multivariable model.
Thurtle DR; Greenberg DC; Lee LS; Huang HH; Pharoah PD; Gnanapragasam VJ
PLoS Med; 2019 Mar; 16(3):e1002758. PubMed ID: 30860997
[TBL] [Abstract] [Full Text] [Related]
14. Sexual minority men and the experience of undergoing treatment for prostate cancer: An integrative review.
Moore MA; Batten J; Lazenby M
Eur J Cancer Care (Engl); 2019 Jul; 28(4):e13031. PubMed ID: 30828899
[TBL] [Abstract] [Full Text] [Related]
15. Time-to-event Outcomes in Men with Nonmetastatic Castrate-resistant prostate cancer-A Systematic Literature Review and Pooling of Individual Participant Data.
Aly M; Hashim M; Heeg B; Liwing J; Leval A; Mehra M; Lawson J; Brookman-May SD; Akre O
Eur Urol Focus; 2019 Sep; 5(5):788-798. PubMed ID: 29627197
[TBL] [Abstract] [Full Text] [Related]
16. Associations Between prostate Volume and Oncologic Outcomes in Men Undergoing Focal Cryoablation of the prostate.
Elshafei A; Tay KJ; Kara O; Malkoc E; Nyame Y; Arora H; Hatem A; Patel SA; Lugnani F; Polascik TJ; Jones JS
Clin Genitourin Cancer; 2018 Apr; 16(2):e477-e482. PubMed ID: 29174470
[TBL] [Abstract] [Full Text] [Related]
17. Testosterone therapy for sexual dysfunction in men with Type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
Algeffari M; Jayasena CN; MacKeith P; Thapar A; Dhillo WS; Oliver N
Diabet Med; 2018 Feb; 35(2):195-202. PubMed ID: 29171080
[TBL] [Abstract] [Full Text] [Related]
18. Budgetary Impact of Cabazitaxel Use After Docetaxel treatment for Metastatic Castration-Resistant prostate cancer.
Flannery K; Drea E; Hudspeth L; Corman S; Gao X; Xue M; Miao R
J Manag Care Spec Pharm; 2017 Apr; 23(4):416-426. PubMed ID: 28345444
[TBL] [Abstract] [Full Text] [Related]
19. Abiraterone Acetate for the treatment of Chemotherapy-Naïve Metastatic Castration-Resistant prostate cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Ramaekers BLT; Riemsma R; Tomini F; van Asselt T; Deshpande S; Duffy S; Armstrong N; Severens JL; Kleijnen J; Joore MA
Pharmacoeconomics; 2017 Feb; 35(2):191-202. PubMed ID: 27566699
[TBL] [Abstract] [Full Text] [Related]
20. Subsequent Chemotherapy and treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant prostate cancer: Post Hoc Analysis of COU-AA-302.
de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
[TBL] [Abstract] [Full Text] [Related]
[Next]
